vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and OR Royalties Inc. (OR). Click either name above to swap in a different company.
OR Royalties Inc. is the larger business by last-quarter revenue ($46.7M vs $27.6M, roughly 1.7× Beta Bionics, Inc.).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
OR Royalties Inc. is a Canadian company that holds royalties in gold, silver and diamond mines, principally in the form of net smelter returns and streams.Like its predecessor company, Osisko Mining, it is headquartered in Montreal, Quebec, with shares listed on the Toronto Stock Exchange and the New York Stock Exchange.
BBNX vs OR — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2022
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $46.7M |
| Net Profit | $-21.9M | — |
| Gross Margin | 59.5% | — |
| Operating Margin | -47.4% | — |
| Net Margin | -79.3% | — |
| Revenue YoY | 56.6% | — |
| Net Profit YoY | 23.6% | — |
| EPS (diluted) | $-0.49 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | — | ||
| Q3 25 | $27.3M | — | ||
| Q2 25 | $23.2M | — | ||
| Q1 25 | $17.6M | — | ||
| Q2 22 | — | $46.7M | ||
| Q1 22 | — | $43.4M |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | — | ||
| Q3 25 | $-14.2M | — | ||
| Q2 25 | $-16.9M | — | ||
| Q1 25 | $-28.7M | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | — | ||
| Q3 25 | 55.5% | — | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 50.9% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | — | ||
| Q3 25 | -62.5% | — | ||
| Q2 25 | -85.5% | — | ||
| Q1 25 | -105.7% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | — | ||
| Q3 25 | -52.1% | — | ||
| Q2 25 | -72.6% | — | ||
| Q1 25 | -162.5% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | — | ||
| Q3 25 | $-0.33 | — | ||
| Q2 25 | $-0.39 | — | ||
| Q1 25 | $-0.93 | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | — |
| Total DebtLower is stronger | — | $222.8M |
| Stockholders' EquityBook value | $271.2M | $1.3B |
| Total Assets | $304.4M | — |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | — | ||
| Q3 25 | $228.7M | — | ||
| Q2 25 | $249.7M | — | ||
| Q1 25 | $231.5M | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 22 | — | $222.8M | ||
| Q1 22 | — | $302.5M |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | — | ||
| Q3 25 | $294.8M | — | ||
| Q2 25 | $301.6M | — | ||
| Q1 25 | $313.8M | — | ||
| Q2 22 | — | $1.3B | ||
| Q1 22 | — | $1.3B |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | — | ||
| Q3 25 | $330.0M | — | ||
| Q2 25 | $330.0M | — | ||
| Q1 25 | $338.0M | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 22 | — | 0.17× | ||
| Q1 22 | — | 0.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
